Just wondering what thoughts were after recent news from Regulus (see Dr. KSS 2/3/16 post).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More InfoYour subscription is paid through your PayPal account.
To update your credit card or cancel, please log in to PayPal.com, go to your automatic payments, open the Stock Gumshoe payment, and make changes there.
More information here: Paypal — What Is an Automatic Payment and How Do I Update or Cancel One?
rgls hasn’t looked good since last march. stay out.
Team,
$RGLS well it sure has performed well since I acquired shares. In fact it is my only current Biotech holding in the green at +35%. Certainly still much closer to its 52 week low ($5.14) than its 52 week high ($21.22) with an average target price of $31. Like many emerging Biotechs it could also be a possible buy out candidate. Earnings on Monday but earnings are far less important with emerging Biotechs.
V/R
Tom
I am thinking along those same lines. Attractive price, possible highly successful drug making 52-week even less meaningful, possible buy-out candidate. Cash burn rate?